Teknova Teams Up with Pluristyx to Enhance Cell Therapy Production
Teknova and Pluristyx Partnership for Cell Therapy Innovation
HOLLISTER, Calif. – Teknova, known for its critical reagents in life sciences, has joined forces with Pluristyx to enhance the manufacturing of next-generation cell therapies. This collaboration aims to produce and distribute the PluriFreeze™ product line, which serves as both a cryopreservative and cell wash media system for developers of allogeneic cell therapies.
Transforming Cellular Biopreservation
Pluristyx has carved a niche in providing induced Pluripotent Stem Cells (iPSCs) and recognizes how crucial proper cellular biopreservation is throughout the cell therapy process. They’ve crafted a unique cryopreservation formulation that allows for systematic freezing of cells, thereby streamlining the cell product manufacturing process. By launching the PluriFreeze product line, they combine advanced cryopreservation with ease of use for companies focused on bringing these therapies to market.
Exclusive Production and Distribution
This partnership signifies that Teknova will serve as the exclusive manufacturer and distributor of PluriFreeze in the United States and Canada, broadening access for customers looking to utilize this groundbreaking product.
Voices Behind the Collaboration
Teknova's President and CEO, Stephen Gunstream, expressed enthusiasm about the collaboration, emphasizing how it unites Teknova’s operational strength with Pluristyx's innovative cryopreservation technology. He remarked that making PluriFreeze readily available will aid customers in streamlining their transition from research stages to clinical manufacturing.
Quality and Experience Matter
Pluristyx's CEO, Benjamin Fryer, noted that with Teknova’s 30 years of experience and an extensive customer base, they are poised perfectly to expand the reach of the PluriFreeze system. The focus on maintaining high cellular viability is critical not just for storage, but throughout every stage of the workflow in cell therapy development.
Understanding PluriFreeze
The PluriFreeze system offers both a synthetic base wash that resembles the intracellular environment and a unique low-viscosity freezing medium containing 10% dimethyl sulfoxide (DMSO). This combination enhances ease of scalability and process automation for manufacturers looking to accelerate their production processes.
Upcoming Announcements
More details about their collaboration and product specifics, including pricing and availability, will soon be revealed during the BioProcess International West conference. This occasion represents a significant opportunity for interested parties to gain insights into the progression of these innovative solutions.
About Teknova
Since its inception, Teknova has been committed to pushing the boundaries of reagent manufacturing to support the life sciences industry. Their customizable solutions help developers accelerate their work, from initial research to large-scale production. Located in Hollister, California, Teknova utilizes a state-of-the-art manufacturing platform to deliver high-quality reagents and media that are essential for new therapeutic advancements.
About Pluristyx
Pluristyx specializes in the development and manufacturing of cell and gene therapies, offering a suite of services that includes iPSC lines and genetic engineering technologies. Their focus on high-quality products is crucial for driving forward the clinical applications of transformative cell therapies.
Frequently Asked Questions
1. What is the purpose of the Teknova and Pluristyx collaboration?
The collaboration focuses on producing and commercializing the PluriFreeze product line, which supports the manufacturing of allogeneic cell therapies.
2. What benefits does PluriFreeze offer?
PluriFreeze enhances cellular biopreservation and simplifies the scale-up process for developers working on cell therapies.
3. How does Teknova contribute to this partnership?
Teknova serves as the exclusive manufacturer and distributor of PluriFreeze in the U.S. and Canada, leveraging their extensive experience and operational capabilities.
4. Where can more information about these products be found?
Detailed information will be available at the BioProcess International West conference and can also be accessed through Teknova's official channels.
5. How long has Teknova been in the life sciences industry?
Teknova has been innovating in the life sciences sector since 1996, focusing on reagent manufacturing and supporting various biomedical applications.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
